

# Marco Rovaris

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2246496/publications.pdf>

Version: 2024-02-01

272  
papers

14,756  
citations

13865

67  
h-index

24982

109  
g-index

277  
all docs

277  
docs citations

277  
times ranked

9729  
citing authors

#	ARTICLE	IF	CITATIONS
1	Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. <i>Lancet, The</i> , 2001, 357, 1576-1582.	13.7	1,025
2	Evidence for widespread axonal damage at the earliest clinical stage of multiple sclerosis. <i>Brain</i> , 2003, 126, 433-437.	7.6	324
3	MRI criteria for multiple sclerosis in patients presenting with clinically isolated syndromes: a multicentre retrospective study. <i>Lancet Neurology, The</i> , 2007, 6, 677-686.	10.2	292
4	Assessing brain atrophy rates in a large population of untreated multiple sclerosis subtypes. <i>Neurology</i> , 2010, 74, 1868-1876.	1.1	284
5	Glatiramer acetate reduces the proportion of new MS lesions evolving into "black holes". <i>Neurology</i> , 2001, 57, 731-733.	1.1	274
6	Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study. <i>Lancet, The</i> , 2008, 371, 2085-2092.	13.7	265
7	Relation between MR abnormalities and patterns of cognitive impairment in multiple sclerosis. <i>Neurology</i> , 1998, 50, 1601-1608.	1.1	253
8	Diffusion MRI in multiple sclerosis. <i>Neurology</i> , 2005, 65, 1526-1532.	1.1	252
9	Interferon beta-1a for brain tissue loss in patients at presentation with syndromes suggestive of multiple sclerosis: a randomised, double-blind, placebo-controlled trial. <i>Lancet, The</i> , 2004, 364, 1489-1496.	13.7	246
10	Secondary progressive multiple sclerosis: current knowledge and future challenges. <i>Lancet Neurology, The</i> , 2006, 5, 343-354.	10.2	246
11	MRI criteria for MS in patients with clinically isolated syndromes. <i>Neurology</i> , 2010, 74, 427-434.	1.1	231
12	MRI and the diagnosis of multiple sclerosis: expanding the concept of "no better explanation". <i>Lancet Neurology, The</i> , 2006, 5, 841-852.	10.2	217
13	Cognitive dysfunction in patients with mildly disabling relapsing-remitting multiple sclerosis: an exploratory study with diffusion tensor MR imaging. <i>Journal of the Neurological Sciences</i> , 2002, 195, 103-109.	0.6	208
14	Assessment of Normal-Appearing White and Gray Matter in Patients With Primary Progressive Multiple Sclerosis. <i>Archives of Neurology</i> , 2002, 59, 1406-12.	4.5	180
15	Changes in the normal appearing brain tissue and cognitive impairment in multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2000, 68, 157-161.	1.9	171
16	In vivo assessment of the brain and cervical cord pathology of patients with primary progressive multiple sclerosis. <i>Brain</i> , 2001, 124, 2540-2549.	7.6	163
17	Nocturnal sleep study in multiple sclerosis: Correlations with clinical and brain magnetic resonance imaging findings. <i>Journal of the Neurological Sciences</i> , 1994, 125, 194-197.	0.6	153
18	Intra-observer reproducibility in measuring new putative MR markers of demyelination and axonal loss in multiple sclerosis: a comparison with conventional T2-weighted images. <i>Journal of Neurology</i> , 1997, 244, 266-270.	3.6	153

#	ARTICLE	IF	CITATIONS
19	Magnetization transfer imaging to monitor the evolution of MS. <i>Neurology</i> , 2000, 55, 940-946.	1.1	145
20	Short-term brain volume change in relapsing-remitting multiple sclerosis: Effect of glatiramer acetate and implications. <i>Brain</i> , 2001, 124, 1803-1812.	7.6	143
21	Magnetization transfer MRI metrics predict the accumulation of disability 8 years later in patients with multiple sclerosis. <i>Brain</i> , 2006, 129, 2620-2627.	7.6	143
22	Glatiramer acetate reduces the proportion of new MS lesions evolving into "black holes". <i>Neurology</i> , 2002, 58, 1440-1442.	1.1	136
23	Age-related Changes in Conventional, Magnetization Transfer, and Diffusion-Tensor MR Imaging Findings: Study with Whole-Brain Tissue Histogram Analysis. <i>Radiology</i> , 2003, 227, 731-738.	7.3	134
24	Multimodal evoked potentials to assess the evolution of multiple sclerosis: a longitudinal study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2006, 77, 1030-1035.	1.9	130
25	Whole brain volume changes in patients with progressive MS treated with cladribine. <i>Neurology</i> , 2000, 55, 1714-1718.	1.1	124
26	A multi-centre longitudinal study comparing the sensitivity of monthly MRI after standard and triple dose gadolinium-DTPA for monitoring disease activity in multiple sclerosis. Implications for phase II clinical trials. <i>Brain</i> , 1998, 121, 2011-2020.	7.6	123
27	Mean diffusivity and fractional anisotropy histogram analysis of the cervical cord in MS patients. <i>NeuroImage</i> , 2005, 26, 822-828.	4.2	123
28	MRI and motor evoked potential findings in nondisabled multiple sclerosis patients with and without symptoms of fatigue. <i>Journal of Neurology</i> , 2000, 247, 506-509.	3.6	122
29	Conventional and magnetization transfer MRI predictors of clinical multiple sclerosis evolution: a medium-term follow-up study. <i>Brain</i> , 2003, 126, 2323-2332.	7.6	122
30	Grey matter damage predicts the evolution of primary progressive multiple sclerosis at 5 years. <i>Brain</i> , 2006, 129, 2628-2634.	7.6	122
31	Validation of diagnostic magnetic resonance imaging criteria for multiple sclerosis and response to interferon $\beta$ 1a. <i>Annals of Neurology</i> , 2003, 53, 718-724.	5.3	120
32	A Single, Early Magnetic Resonance Imaging Study in the Diagnosis of Multiple Sclerosis. <i>Archives of Neurology</i> , 2009, 66, 587-92.	4.5	114
33	Measurement error of two different techniques for brain atrophy assessment in multiple sclerosis. <i>Neurology</i> , 2004, 62, 1432-1434.	1.1	113
34	Regional brain atrophy evolves differently in patients with multiple sclerosis according to clinical phenotype. <i>American Journal of Neuroradiology</i> , 2005, 26, 341-6.	2.4	113
35	Influence of aging on brain gray and white matter changes assessed by conventional, MT, and DT MRI. <i>Neurology</i> , 2006, 66, 535-539.	1.1	109
36	Brain involvement in systemic immune mediated diseases: magnetic resonance and magnetisation transfer imaging study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2000, 68, 170-177.	1.9	107

#	ARTICLE	IF	CITATIONS
37	One year follow up study of primary and transitional progressive multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2000, 68, 713-718.	1.9	106
38	Short-term accrual of gray matter pathology in patients with progressive multiple sclerosis: an in vivo study using diffusion tensor MRI. NeuroImage, 2005, 24, 1139-1146.	4.2	106
39	Fatigue and magnetic resonance imaging activity in multiple sclerosis. Journal of Neurology, 1999, 246, 454-458.	3.6	104
40	Improving interobserver variation in reporting gadolinium-enhanced MRI lesions in multiple sclerosis. Neurology, 1997, 49, 1682-1688.	1.1	103
41	Progressive Gray Matter Damage in Patients With Relapsing-Remitting Multiple Sclerosis. Archives of Neurology, 2005, 62, 578.	4.5	103
42	Electroencephalographic coherence analysis in multiple sclerosis: correlation with clinical, neuropsychological, and MRI findings. Journal of Neurology, Neurosurgery and Psychiatry, 2000, 69, 192-198.	1.9	101
43	Diffusion-Tensor Magnetic Resonance Imaging Detects Normal-Appearing White Matter Damage Unrelated to Short-term Disease Activity in Patients at the Earliest Clinical Stage of Multiple Sclerosis. Archives of Neurology, 2005, 62, 803.	4.5	101
44	Predicting progression in primary progressive multiple sclerosis: A 10-year multicenter study. Annals of Neurology, 2008, 63, 790-793.	5.3	101
45	Quantification of cervical cord pathology in primary progressive MS using diffusion tensor MRI. Neurology, 2005, 64, 631-635.	1.1	99
46	Corpus callosum damage and cognitive dysfunction in benign MS. Human Brain Mapping, 2009, 30, 2656-2666.	3.6	99
47	Recommendations to improve imaging and analysis of brain lesion load and atrophy in longitudinal studies of multiple sclerosis. Journal of Neurology, 2013, 260, 2458-2471.	3.6	96
48	Brain magnetic resonance imaging correlates of cognitive impairment in multiple sclerosis. Journal of the Neurological Sciences, 1993, 115, S66-S73.	0.6	95
49	Magnetic resonance imaging correlates of physical disability in relapse onset multiple sclerosis of long disease duration. Multiple Sclerosis Journal, 2014, 20, 72-80.	3.0	95
50	Efficacy and safety of cannabinoid oromucosal spray for multiple sclerosis spasticity. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, 944-951.	1.9	88
51	Cognitive impairment and structural brain damage in benign multiple sclerosis. Neurology, 2008, 71, 1521-1526.	1.1	85
52	The effect of interferon $\beta$ -1b on quantities derived from MT MRI in secondary progressive MS. Neurology, 2003, 60, 853-860.	1.1	84
53	Costimulatory Pathways in Multiple Sclerosis: Distinctive Expression of PD-1 and PD-L1 in Patients with Different Patterns of Disease. Journal of Immunology, 2009, 183, 4984-4993.	0.8	83
54	Magnetization transfer ratios in multiple sclerosis lesions enhancing after different doses of gadolinium. Neurology, 1998, 50, 1289-1293.	1.1	81

#	ARTICLE	IF	CITATIONS
55	Intercenter differences in diffusion tensor MRI acquisition. <i>Journal of Magnetic Resonance Imaging</i> , 2010, 31, 1458-1468.	3.4	81
56	MRI characteristics of atypical idiopathic inflammatory demyelinating lesions of the brain. <i>Journal of Neurology</i> , 2008, 255, 1-10.	3.6	80
57	Will Rogers phenomenon in multiple sclerosis. <i>Annals of Neurology</i> , 2008, 64, 428-433.	5.3	80
58	Magnetic resonance techniques to monitor disease evolution and treatment trial outcomes in multiple sclerosis. <i>Current Opinion in Neurology</i> , 1999, 12, 337-344.	3.6	80
59	Relative contributions of brain and cervical cord pathology to multiple sclerosis disability: a study with magnetisation transfer ratio histogram analysis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2000, 69, 723-727.	1.9	78
60	Evidence for relative cortical sparing in benign multiple sclerosis: a longitudinal magnetic resonance imaging study. <i>Multiple Sclerosis Journal</i> , 2009, 15, 36-41.	3.0	78
61	Assessment of Disease Activity in Multiple Sclerosis Phenotypes with Combined Gadolinium- and Superparamagnetic Iron Oxide-enhanced MR Imaging. <i>Radiology</i> , 2012, 264, 225-233.	7.3	75
62	Mitoxantrone for multiple sclerosis. <i>The Cochrane Library</i> , 2013, , CD002127.	2.8	75
63	Normal-appearing white and grey matter damage in MS. <i>Journal of Neurology</i> , 2007, 254, 513-518.	3.6	73
64	Diffusion Tensor MR Imaging. <i>Neuroimaging Clinics of North America</i> , 2009, 19, 37-43.	1.0	73
65	Effects of glatiramer acetate on relapse rate and accumulated disability in multiple sclerosis: meta-analysis of three double-blind, randomized, placebo-controlled clinical trials. <i>Multiple Sclerosis Journal</i> , 2003, 9, 349-355.	3.0	72
66	Evidence for progressive gray matter loss in patients with relapsing-remitting MS. <i>Neurology</i> , 2005, 65, 1126-1128.	1.1	72
67	Method for intracellular magnetic labeling of human mononuclear cells using approved iron contrast agents. <i>Magnetic Resonance Imaging</i> , 1999, 17, 1521-1523.	1.8	69
68	Indoleamine 2,3 Dioxygenase (IDO) Expression and Activity in Relapsing- Remitting Multiple Sclerosis. <i>PLoS ONE</i> , 2015, 10, e0130715.	2.5	69
69	Magnetic resonance imaging, magnetisation transfer imaging, and diffusion weighted imaging correlates of optic nerve, brain, and cervical cord damage in Leber's hereditary optic neuropathy. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2001, 70, 444-449.	1.9	68
70	MRI markers of destructive pathology in multiple sclerosis-related cognitive dysfunction. <i>Journal of the Neurological Sciences</i> , 2006, 245, 111-116.	0.6	68
71	MRI monitoring of immunomodulation in relapse-onset multiple sclerosis trials. <i>Nature Reviews Neurology</i> , 2012, 8, 13-21.	10.1	67
72	The effect of cladribine on T1 "black hole" changes in progressive MS. <i>Journal of the Neurological Sciences</i> , 2000, 176, 42-44.	0.6	64

#	ARTICLE	IF	CITATIONS
73	A Magnetic Resonance Imaging Voxel-Based Morphometry Study of Regional Gray Matter Atrophy in Patients With Benign Multiple Sclerosis. <i>Archives of Neurology</i> , 2008, 65, 1223-30.	4.5	64
74	Long-term clinical outcome of primary progressive MS: Predictive value of clinical and MRI data. <i>Neurology</i> , 2005, 65, 633-635.	1.1	59
75	Diffusion Tensor MRI in Multiple Sclerosis. <i>Journal of Neuroimaging</i> , 2007, 17, 27S-30S.	2.0	59
76	The Italian multiple sclerosis register. <i>Neurological Sciences</i> , 2019, 40, 155-165.	1.9	59
77	Large-scale, multicentre, quantitative MRI study of brain and cord damage in primary progressive multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2008, 14, 455-464.	3.0	58
78	Integrated telerehabilitation approach in multiple sclerosis: A systematic review and meta-analysis. <i>Journal of Telemedicine and Telecare</i> , 2020, 26, 385-399.	2.7	58
79	Delivery to the Central Nervous System of a Nonreplicative Herpes Simplex Type 1 Vector Engineered with the Interleukin 4 Gene Protects Rhesus Monkeys from Hyperacute Autoimmune Encephalomyelitis. <i>Human Gene Therapy</i> , 2001, 12, 905-920.	2.7	57
80	Interferon beta for secondary progressive multiple sclerosis. <i>The Cochrane Library</i> , 2012, 1, CD005181.	2.8	57
81	Correlations Between Clinical Findings and Magnetization Transfer Imaging Metrics of Tissue Damage in Individuals With Cerebral Autosomal Dominant Arteriopathy With Subcortical Infarcts and Leukoencephalopathy. <i>Stroke</i> , 2001, 32, 643-648.	2.0	56
82	Occult tissue damage in patients with primary progressive multiple sclerosis is independent of T2-visible lesions. <i>Journal of Neurology</i> , 2003, 250, 456-460.	3.6	56
83	T helper-17 activation dominates the immunologic milieu of both amyotrophic lateral sclerosis and progressive multiple sclerosis. <i>Clinical Immunology</i> , 2013, 148, 79-88.	3.2	56
84	Morphology and evolution of cortical lesions in multiple sclerosis. A longitudinal MRI study. <i>NeuroImage</i> , 2008, 42, 1324-1328.	4.2	55
85	Online meditation training for people with multiple sclerosis: A randomized controlled trial. <i>Multiple Sclerosis Journal</i> , 2019, 25, 610-617.	3.0	55
86	Clinical trials of multiple sclerosis monitored with enhanced MRI: new sample size calculations based on large data sets. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2001, 70, 494-499.	1.9	54
87	Impaired Short-term Motor Learning in Multiple Sclerosis: Evidence From Virtual Reality. <i>Neurorehabilitation and Neural Repair</i> , 2007, 21, 273-278.	2.9	54
88	Effects of motor rehabilitation on mobility and brain plasticity in multiple sclerosis: a structural and functional MRI study. <i>Journal of Neurology</i> , 2018, 265, 1393-1401.	3.6	54
89	Long-term follow-up of patients treated with glatiramer acetate: a multicentre, multinational extension of the European/Canadian double-blind, placebo-controlled, MRI-monitored trial. <i>Multiple Sclerosis Journal</i> , 2007, 13, 502-508.	3.0	53
90	T2 lesion location really matters: a 10 year follow-up study in primary progressive multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2011, 82, 72-77.	1.9	53

#	ARTICLE	IF	CITATIONS
91	Effects of natalizumab on oligoclonal bands in the cerebrospinal fluid of multiple sclerosis patients: A longitudinal study. <i>Multiple Sclerosis Journal</i> , 2014, 20, 1900-1903.	3.0	52
92	Sensitivity and reproducibility of volume change measurements of different brain portions on magnetic resonance imaging in patients with multiple sclerosis. <i>Journal of Neurology</i> , 2000, 247, 960-965.	3.6	51
93	Long-term disability progression in primary progressive multiple sclerosis: a 15-year study. <i>Brain</i> , 2017, 140, 2814-2819.	7.6	51
94	Prediction of Falls in Subjects Suffering From Parkinson Disease, Multiple Sclerosis, and Stroke. <i>Archives of Physical Medicine and Rehabilitation</i> , 2018, 99, 641-651.	0.9	51
95	Neuroimaging in amyotrophic lateral sclerosis. <i>European Journal of Neurology</i> , 1999, 6, 629-637.	3.3	48
96	A multiparametric MRI study of frontal lobe dementia in multiple sclerosis. <i>Journal of the Neurological Sciences</i> , 1999, 171, 135-144.	0.6	48
97	Axonal injury in early multiple sclerosis is irreversible and independent of the short-term disease evolution. <i>Neurology</i> , 2005, 65, 1626-1630.	1.1	48
98	MRI features of benign multiple sclerosis. <i>Neurology</i> , 2009, 72, 1693-1701.	1.1	48
99	Oxidative Stress Is Differentially Present in Multiple Sclerosis Courses, Early Evident, and Unrelated to Treatment. <i>Journal of Immunology Research</i> , 2014, 2014, 1-9.	2.2	48
100	Whole-brain atrophy in multiple sclerosis measured by two segmentation processes from various MRI sequences. <i>Journal of the Neurological Sciences</i> , 2003, 216, 169-177.	0.6	47
101	Determinants of Disability in Multiple Sclerosis at Various Disease Stages. <i>Archives of Neurology</i> , 2007, 64, 1163.	4.5	47
102	Interferon $\beta$ for secondary progressive multiple sclerosis: a systematic review. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2013, 84, 420-426.	1.9	47
103	Safety of the first dose of fingolimod for multiple sclerosis: results of an open-label clinical trial. <i>BMC Neurology</i> , 2014, 14, 65.	1.8	47
104	Longitudinal associations between mindfulness and well-being in people with multiple sclerosis. <i>International Journal of Clinical and Health Psychology</i> , 2019, 19, 22-30.	5.1	47
105	Interferons-beta versus glatiramer acetate for relapsing-remitting multiple sclerosis. <i>The Cochrane Library</i> , 2016, 2016, CD009333.	2.8	46
106	A high-resolution three-dimensional T <sub>1</sub> -weighted gradient echo sequence improves the detection of disease activity in multiple sclerosis. <i>Annals of Neurology</i> , 1996, 40, 901-907.	5.3	45
107	Randomized, double-blind, dose-comparison study of glatiramer acetate in relapsing-remitting MS. <i>Neurology</i> , 2007, 68, 939-944.	1.1	45
108	Intercenter agreement of brain atrophy measurement in multiple sclerosis patients using manually-edited SIENA and SIENAX. <i>Journal of Magnetic Resonance Imaging</i> , 2007, 26, 881-885.	3.4	45

#	ARTICLE	IF	CITATIONS
109	MicroRNA-572 expression in multiple sclerosis patients with different patterns of clinical progression. <i>Journal of Translational Medicine</i> , 2015, 13, 148.	4.4	45
110	HLA alleles modulate EBV viral load in multiple sclerosis. <i>Journal of Translational Medicine</i> , 2018, 16, 80.	4.4	44
111	Two-year follow-up study of primary and transitional progressive multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2002, 8, 108-114.	3.0	43
112	An MT MRI study of the cervical cord in clinically isolated syndromes suggestive of MS. <i>Neurology</i> , 2004, 63, 584-585.	1.1	42
113	Are Modular Activations Altered in Lower Limb Muscles of Persons with Multiple Sclerosis during Walking? Evidence from Muscle Synergies and Biomechanical Analysis. <i>Frontiers in Human Neuroscience</i> , 2016, 10, 620.	2.0	42
114	Immunological patterns identifying disease course and evolution in multiple sclerosis patients. <i>Journal of Neuroimmunology</i> , 2005, 165, 192-200.	2.3	38
115	A diffusion tensor MRI study of cervical cord damage in benign and secondary progressive multiple sclerosis patients. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2010, 81, 26-30.	1.9	38
116	Patterns of disease activity in multiple sclerosis patients: A study with quantitative gadolinium-enhanced brain MRI and cytokine measurement in different clinical subgroups. <i>Journal of Neurology</i> , 1996, 243, 536-542.	3.6	37
117	A Longitudinal Magnetic Resonance Imaging Study of the Cervical Cord in Multiple Sclerosis. <i>Journal of Neuroimaging</i> , 1997, 7, 78-80.	2.0	37
118	Intensive Multimodal Training to Improve Gait Resistance, Mobility, Balance and Cognitive Function in Persons With Multiple Sclerosis: A Pilot Randomized Controlled Trial. <i>Frontiers in Neurology</i> , 2018, 9, 800.	2.4	37
119	Axonal Injury and Overall Tissue Loss Are Not Related in Primary Progressive Multiple Sclerosis. <i>Archives of Neurology</i> , 2005, 62, 898-902.	4.5	36
120	A 3-year diffusion tensor MRI study of grey matter damage progression during the earliest clinical stage of MS. <i>Journal of Neurology</i> , 2008, 255, 1209-1214.	3.6	36
121	A simple and universal enzyme-free approach for the detection of multiple microRNAs using a single nanostructured enhancer of surface plasmon resonance imaging. <i>Analytical and Bioanalytical Chemistry</i> , 2019, 411, 1873-1885.	3.7	36
122	Frequency and patterns of subclinical cognitive impairment in patients with ANCA-associated small vessel vasculitides. <i>Journal of the Neurological Sciences</i> , 2002, 195, 161-166.	0.6	35
123	Primary progressive multiple sclerosis diagnostic criteria: a reappraisal. <i>Multiple Sclerosis Journal</i> , 2009, 15, 1459-1465.	3.0	35
124	An MR study of tissue damage in the cervical cord of patients with migraine. <i>Journal of the Neurological Sciences</i> , 2001, 183, 43-46.	0.6	34
125	A reassessment of the plateauing relationship between T2 lesion load and disability in MS. <i>Neurology</i> , 2009, 73, 1538-1542.	1.1	34
126	Corticospinal tract integrity is related to primary motor cortex thinning in relapsing&acircumremitting multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2015, 21, 1771-1780.	3.0	34



#	ARTICLE	IF	CITATIONS
127	B Lymphocytes in Multiple Sclerosis: Bregs and BTLA/CD272 Expressing-CD19+ Lymphocytes Modulate Disease Severity. <i>Scientific Reports</i> , 2016, 6, 29699.	3.3	34
128	Somatosensory evoked potentials and sensory involvement in multiple sclerosis: comparison with clinical findings and quantitative sensory tests. <i>Multiple Sclerosis Journal</i> , 2003, 9, 275-279.	3.0	33
129	Imaging primary progressive multiple sclerosis: the contribution of structural, metabolic, and functional MRI techniques. <i>Multiple Sclerosis Journal</i> , 2004, 10, S36-S45.	3.0	33
130	A composite score to predict short-term disease activity in patients with relapsing-remitting MS. <i>Neurology</i> , 2007, 69, 1230-1235.	1.1	33
131	Two-year real-life efficacy, tolerability and safety of dimethyl fumarate in an Italian multicentre study. <i>Journal of Neurology</i> , 2018, 265, 1850-1859.	3.6	33
132	Effects of seasons on magnetic resonance imaging-measured disease activity in patients with multiple sclerosis. <i>Annals of Neurology</i> , 2001, 49, 415-416.	5.3	32
133	Semi-automated thresholding technique for measuring lesion volumes in multiple sclerosis: effects of the change of the threshold on the computed lesion loads. <i>Acta Neurologica Scandinavica</i> , 1996, 93, 30-34.	2.1	30
134	A role for the TIM3/GAL9/BAT3 pathway in determining the clinical phenotype of multiple sclerosis. <i>FASEB Journal</i> , 2014, 28, 5000-5009.	0.5	30
135	Mitoxantrone for multiple sclerosis. , 2005, , CD002127.		29
136	Monosodium Urate Crystals Activate the Inflammasome in Primary Progressive Multiple Sclerosis. <i>Frontiers in Immunology</i> , 2018, 9, 983.	4.8	29
137	Brain MRI correlates of magnetization transfer imaging metrics in patients with multiple sclerosis. <i>Journal of the Neurological Sciences</i> , 1999, 166, 58-63.	0.6	28
138	Brain Stem Magnetic Resonance Imaging and Evoked Potential Studies of Symptomatic Multiple Sclerosis Patients. <i>European Neurology</i> , 1993, 33, 232-237.	1.4	27
139	Acute myelopathy of unknown aetiology: a clinical, neurophysiological and MRI study of short-and long-term prognostic factors. <i>Journal of Neurology</i> , 1995, 242, 497-503.	3.6	26
140	Effect of glatiramer acetate on MS lesions enhancing at different gadolinium doses. <i>Neurology</i> , 2002, 59, 1429-1432.	1.1	26
141	Magnetic Resonance Imaging of Multiple Sclerosis. <i>Journal of Neuroimaging</i> , 2002, 12, 289-301.	2.0	26
142	A novel data mining system points out hidden relationships between immunological markers in multiple sclerosis. <i>Immunity and Ageing</i> , 2013, 10, 1.	4.2	26
143	A comparison of conventional and fast spin-echo sequences for the measurement of lesion load in multiple sclerosis using a semi-automated contour technique. <i>Neuroradiology</i> , 1997, 39, 161-165.	2.2	25
144	Cervical cord magnetic resonance imaging findings in systemic immune-mediated diseases. <i>Journal of the Neurological Sciences</i> , 2000, 176, 128-130.	0.6	25

#	ARTICLE	IF	CITATIONS
145	DTI Parameter Optimisation for Acquisition at 1.5T: SNR Analysis and Clinical Application. Computational Intelligence and Neuroscience, 2010, 2010, 1-8.	1.7	25
146	White Matter Tract Injury is Associated with Deep Gray Matter Iron Deposition in Multiple Sclerosis. Journal of Neuroimaging, 2017, 27, 107-113.	2.0	25
147	The contribution of fast-FLAIR MRI for lesion detection in the brain of patients with systemic autoimmune diseases. Journal of Neurology, 2000, 247, 29-33.	3.6	24
148	Sativex in resistant multiple sclerosis spasticity: Discontinuation study in a large population of Italian patients (SA.FE. study). PLoS ONE, 2017, 12, e0180651.	2.5	24
149	The Effects of Transcutaneous Spinal Direct Current Stimulation on Neuropathic Pain in Multiple Sclerosis: Clinical and Neurophysiological Assessment. Frontiers in Human Neuroscience, 2019, 13, 31.	2.0	24
150	Social Cognition Training for Enhancing Affective and Cognitive Theory of Mind in Schizophrenia: A Systematic Review and a Meta-Analysis. Journal of Psychology: Interdisciplinary and Applied, 2021, 155, 26-58.	1.6	24
151	Short-term correlations between clinical and MR imaging findings in relapsing-remitting multiple sclerosis. American Journal of Neuroradiology, 2003, 24, 75-81.	2.4	24
152	The value of new magnetic resonance techniques in multiple sclerosis. Current Opinion in Neurology, 2000, 13, 249-254.	3.6	23
153	Fingolimod effects on left ventricular function in multiple sclerosis. Multiple Sclerosis Journal, 2016, 22, 201-211.	3.0	23
154	Cardiac autonomic function during sleep and wakefulness in multiple sclerosis. Journal of Neurology, 1995, 242, 639-643.	3.6	22
155	Interferon beta treatment for multiple sclerosis has a graduated effect on MRI enhancing lesions according to their size and pathology. Journal of Neurology, Neurosurgery and Psychiatry, 1999, 67, 386-389.	1.9	22
156	Movement preparation is affected by tissue damage in multiple sclerosis: Evidence from EEG event-related desynchronization. Clinical Neurophysiology, 2005, 116, 1515-1519.	1.5	22
157	In-vivo evidence for stable neuroaxonal damage in the brain of patients with benign multiple sclerosis. Multiple Sclerosis Journal, 2009, 15, 789-794.	3.0	22
158	A telemedicine meditation intervention for people with multiple sclerosis and their caregivers: study protocol for a randomized controlled trial. Trials, 2016, 17, 4.	1.6	22
159	Quantitative brain volumetric analysis from patients with multiple sclerosis: a follow-up study. Journal of the Neurological Sciences, 1999, 171, 8-10.	0.6	21
160	A comparison of the sensitivity of MRI after double- and triple-dose Gd-DTPA for detecting enhancing lesions in multiple sclerosis. Magnetic Resonance Imaging, 2000, 18, 761-763.	1.8	21
161	Assessment of the damage of the cerebral hemispheres in MS using neuroimaging techniques. Journal of the Neurological Sciences, 2000, 172, S63-S66.	0.6	21
162	Sensitivity and Reproducibility of Fast-FLAIR, FSE, and TGSE Sequences for the MRI Assessment of Brain Lesion Load in Multiple Sclerosis: A Preliminary Study. Journal of Neuroimaging, 1997, 7, 98-102.	2.0	20

#	ARTICLE	IF	CITATIONS
163	Differential diagnosis of posterior fossa multiple sclerosis lesions - neuroradiological aspects. <i>Neurological Sciences</i> , 2001, 22, S79-S83.	1.9	20
164	A diffusion tensor MRI study of basal ganglia from patients with ADEM. <i>Journal of the Neurological Sciences</i> , 2003, 206, 27-30.	0.6	20
165	The use of magnetic resonance imaging in multiple sclerosis: lessons learned from clinical trials. <i>Multiple Sclerosis Journal</i> , 2004, 10, 341-347.	3.0	20
166	Incorporating Domain Knowledge Into the Fuzzy Connectedness Framework: Application to Brain Lesion Volume Estimation in Multiple Sclerosis. <i>IEEE Transactions on Medical Imaging</i> , 2007, 26, 1670-1680.	8.9	20
167	Endovascular treatment of CCSVI in patients with multiple sclerosis: clinical outcome of 462 cases. <i>Neurological Sciences</i> , 2013, 34, 1633-1637.	1.9	20
168	Italian consensus on treatment of spasticity in multiple sclerosis. <i>European Journal of Neurology</i> , 2020, 27, 445-453.	3.3	20
169	Agreement between different input image types in brain atrophy measurement in multiple sclerosis using SIENAX and SIENA. <i>Journal of Magnetic Resonance Imaging</i> , 2008, 28, 559-565.	3.4	19
170	Modulation of the central memory and Tr1-like regulatory T cells in multiple sclerosis patients responsive to interferon-beta therapy. <i>Multiple Sclerosis Journal</i> , 2012, 18, 788-798.	3.0	19
171	Insights from magnetic resonance imaging. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2014, 122, 115-149.	1.8	19
172	Transition to secondary progression in relapsing-onset multiple sclerosis: Definitions and risk factors. <i>Multiple Sclerosis Journal</i> , 2021, 27, 430-438.	3.0	19
173	JC virus detection and JC virus-specific immunity in natalizumab-treated Multiple Sclerosis patients. <i>Journal of Translational Medicine</i> , 2012, 10, 248.	4.4	18
174	Interferons-beta versus glatiramer acetate for relapsing-remitting multiple sclerosis. , 2014, , CD009333.		18
175	Serial Whole-Brain N-Acetylaspartate Concentration in Healthy Young Adults. <i>American Journal of Neuroradiology</i> , 2007, 28, 1650-1651.	2.4	17
176	Adverse events after endovascular treatment of chronic cerebro-spinal venous insufficiency (CCSVI) in patients with multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2013, 19, 961-963.	3.0	17
177	Drug therapy for multiple sclerosis. <i>Cmaj</i> , 2014, 186, 833-840.	2.0	17
178	The effect of repositioning on brain MRI lesion load assessment in multiple sclerosis: reliability of subjective quality criteria. <i>Journal of Neurology</i> , 1998, 245, 273-275.	3.6	16
179	Lesion load quantification on fast-FLAIR, rapid acquisition relaxation-enhanced, and gradient spin echo brain MRI scans from multiple sclerosis patients. <i>Magnetic Resonance Imaging</i> , 1999, 17, 1105-1110.	1.8	16
180	Short-term evolution of new multiple sclerosis lesions enhancing on standard and triple dose gadolinium-enhanced brain MRI scans. <i>Journal of the Neurological Sciences</i> , 1999, 164, 148-152.	0.6	16

#	ARTICLE	IF	CITATIONS
181	A brain magnetization transfer MRI study with a clinical follow up of about four years in patients with clinically isolated syndromes suggestive of multiple sclerosis. <i>Journal of Neurology</i> , 2007, 254, 78-83.	3.6	16
182	Toll-like receptor 3 differently modulates inflammation in progressive or benign multiple sclerosis. <i>Clinical Immunology</i> , 2014, 150, 109-120.	3.2	16
183	Effects of home-based virtual reality telerehabilitation system in people with multiple sclerosis: A randomized controlled trial. <i>Journal of Telemedicine and Telecare</i> , 2024, 30, 344-355.	2.7	16
184	Cumulative effect of a weekly low dose of interferon beta 1a on standard and triple dose contrast-enhanced MRI from multiple sclerosis patients. <i>Journal of the Neurological Sciences</i> , 1999, 171, 130-134.	0.6	15
185	Sample size estimations for MRI-monitored trials of MS comparing new vs standard treatments. <i>Neurology</i> , 2001, 57, 1883-1885.	1.1	15
186	The role of non-conventional MR techniques to study multiple sclerosis patients. <i>Journal of the Neurological Sciences</i> , 2001, 186, S3-S9.	0.6	15
187	Contribution of cervical cord MRI and brain magnetization transfer imaging to the assessment of individual patients with multiple sclerosis: a preliminary study. <i>Multiple Sclerosis Journal</i> , 2002, 8, 52-58.	3.0	15
188	Can rate of brain atrophy in multiple sclerosis be explained by clinical and MRI characteristics?. <i>Multiple Sclerosis Journal</i> , 2009, 15, 465-471.	3.0	15
189	MRI evolution of new MS lesions enhancing after different doses of gadolinium. <i>Acta Neurologica Scandinavica</i> , 1998, 98, 90-93.	2.1	15
190	A Preliminary Study Comparing the Sensitivity of Serial Monthly Enhanced MRI After Standard and Triple Dose Gadoliniumâ€DTPA for Monitoring Disease Activity in Primary Progressive Multiple Sclerosis. <i>Journal of Neuroimaging</i> , 1998, 8, 88-93.	2.0	14
191	Correlation between MRI and Short-Term Clinical Activity in Multiple Sclerosis: Comparison between Standard- and Triple-Dose Gd-Enhanced MRI. <i>European Neurology</i> , 1999, 41, 123-127.	1.4	14
192	Interventions for the Prevention of Brain Atrophy in Multiple Sclerosis. <i>CNS Drugs</i> , 2003, 17, 563-575.	5.9	14
193	beta endorphin concentrations in PBMC of patients with different clinical phenotypes of multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2003, 74, 495-497.	1.9	14
194	Diffusion tensor MRI of the cervical cord in a patient with syringomyelia and multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2004, 75, 1647-1647.	1.9	14
195	Opposite effects of interferon-beta on new B and T cell release from production sites in multiple sclerosis patients. <i>Journal of Neuroimmunology</i> , 2011, 240-241, 147-150.	2.3	14
196	Mindfulness-Based Interventions for the Improvement of Well-Being in People With Multiple Sclerosis: A Systematic Review and Meta-Analysis. <i>Psychosomatic Medicine</i> , 2020, 82, 600-613.	2.0	14
197	Pattern Visual Evoked Potential Mapping in Alzheimers Disease Correlations with Visuospatial Impairment. <i>Dementia and Geriatric Cognitive Disorders</i> , 1996, 7, 63-68.	1.5	13
198	Antonâ€™s Syndrome following Callosal Disconnectionâ€. <i>Behavioural Neurology</i> , 2007, 18, 183-186.	2.1	13

#	ARTICLE	IF	CITATIONS
199	Absence of diffuse cervical cord tissue damage in early, non-disabling relapsing-remitting MS: a preliminary study. <i>Multiple Sclerosis Journal</i> , 2008, 14, 853-856.	3.0	13
200	Determinants of Disability in Multiple Sclerosis: An Immunological and MRI Study. <i>BioMed Research International</i> , 2014, 2014, 1-8.	1.9	13
201	Comparative efficacy of interferon $\beta$ versus glatiramer acetate for relapsing-remitting multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2015, 86, 1016-1020.	1.9	13
202	Grey matter damage in progressive multiple sclerosis versus amyotrophic lateral sclerosis: a voxel-based morphometry MRI study. <i>Neurological Sciences</i> , 2015, 36, 371-377.	1.9	13
203	Reproducibility of Brain MRI Lesion Volume Measurements in Multiple Sclerosis Using a Local Thresholding Technique: Effects of Formal Operator Training. <i>European Neurology</i> , 1999, 41, 226-230.	1.4	12
204	Multiple sclerosis: interobserver agreement in reporting active lesions on serial brain MRI using conventional spin echo, fast spin echo, fast fluid-attenuated inversion recovery and post-contrast T1-weighted images. <i>Journal of Neurology</i> , 1999, 246, 920-925.	3.6	12
205	Clinical and MRI assessment of brain damage in MS. <i>Neurological Sciences</i> , 2001, 22, S123-S127.	1.9	12
206	Magnetic resonance-based techniques for the study and management of multiple sclerosis. <i>British Medical Bulletin</i> , 2003, 65, 133-144.	6.9	12
207	A longitudinal brain MRI study comparing the sensitivities of the conventional and a newer approach for detecting active lesions in multiple sclerosis. <i>Journal of the Neurological Sciences</i> , 1998, 159, 94-101.	0.6	11
208	Relationship between brain MRI lesion load and short-term disease evolution in non-disabling MS: a large-scale, multicentre study. <i>Multiple Sclerosis Journal</i> , 2011, 17, 319-326.	3.0	11
209	Predictors of effectiveness of multidisciplinary rehabilitation treatment on motor dysfunction in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2014, 20, 862-870.	3.0	11
210	Prevalence and patterns of subclinical motor and cognitive impairments in non-disabled individuals with early multiple sclerosis: A multicenter cross-sectional study. <i>Annals of Physical and Rehabilitation Medicine</i> , 2022, 65, 101491.	2.3	11
211	Defining the response to multiple sclerosis treatment: the role of conventional magnetic resonance imaging. <i>Neurological Sciences</i> , 2005, 26, s204-s208.	1.9	10
212	Signal-to-noise ratio of diffusion weighted magnetic resonance imaging: Estimation methods and in vivo application to spinal cord. <i>Biomedical Signal Processing and Control</i> , 2012, 7, 285-294.	5.7	10
213	A new method for analyzing histograms of brain magnetization transfer ratios: comparison with existing techniques. <i>American Journal of Neuroradiology</i> , 2004, 25, 1234-41.	2.4	10
214	A Comparison Between the Sensitivities of 3mm and 5mm Thick Serial Brain MRI for Detecting Lesion Volume Changes in Patients with Multiple Sclerosis. <i>Journal of Neuroimaging</i> , 1998, 8, 144-147.	2.0	9
215	A comparison of the sensitivity of monthly unenhanced and enhanced MRI techniques in detecting new multiple sclerosis lesions. <i>Journal of Neurology</i> , 1999, 246, 97-106.	3.6	9
216	A Deficit of CEACAM-1-Expressing T Lymphocytes Supports Inflammation in Primary Progressive Multiple Sclerosis. <i>Journal of Immunology</i> , 2019, 203, 76-83.	0.8	9

#	ARTICLE	IF	CITATIONS
217	Improved Gait of Persons With Multiple Sclerosis After Rehabilitation: Effects on Lower Limb Muscle Synergies, Push-Off, and Toe-Clearance. <i>Frontiers in Neurology</i> , 2020, 11, 668.	2.4	9
218	Correlation between enhancing lesion number and volume on standard and triple dose gadolinium-enhanced brain MRI scans from patients with multiple sclerosis. <i>Magnetic Resonance Imaging</i> , 1999, 17, 985-988.	1.8	8
219	The role of magnetic resonance in the assessment of multiple sclerosis. <i>Journal of the Neurological Sciences</i> , 2000, 172, S3-S12.	0.6	8
220	Magnetization transfer and diffusion tensor MR imaging of the optic radiations and calcarine cortex from patients with Leber's hereditary optic neuropathy. <i>Journal of the Neurological Sciences</i> , 2001, 188, 33-36.	0.6	8
221	Indoleamine-2,3-dioxygenase(IDO)2 polymorphisms are not associated with multiple sclerosis in Italians. <i>Journal of the Neurological Sciences</i> , 2017, 377, 31-34.	0.6	8
222	Can glatiramer acetate reduce brain atrophy development in multiple sclerosis?. <i>Journal of the Neurological Sciences</i> , 2005, 233, 139-143.	0.6	7
223	Assessing "occult" cervical cord damage in patients with neuropsychiatric systemic lupus erythematosus using diffusion tensor MRI. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2007, 78, 893-895.	1.9	7
224	TH17-Driven Inflammation is Present in All Clinical Forms of Multiple Sclerosis; Disease Quiescence is Associated with Gata3-Expressing Cells. <i>European Journal of Inflammation</i> , 2013, 11, 223-235.	0.5	7
225	Diagnostic tools for assessment of urinary dysfunction in MS patients without urinary disturbances. <i>Neurological Sciences</i> , 2016, 37, 437-442.	1.9	7
226	Cardiac autonomic function during postural changes and exercise in people with multiple sclerosis: A cross-sectional study. <i>Multiple Sclerosis and Related Disorders</i> , 2018, 24, 85-90.	2.0	7
227	Effect of arm cycling and task-oriented exercises on fatigue and upper limb performance in multiple sclerosis: a randomized crossover study. <i>International Journal of Rehabilitation Research</i> , 2019, 42, 300-308.	1.3	7
228	Detection of multiple sclerosis lesions using EPI-FLAIR images. <i>Magnetic Resonance Imaging</i> , 2000, 18, 907-910.	1.8	6
229	Clinical trials and clinical practice in multiple sclerosis: Conventional and emerging magnetic resonance imaging technologies. <i>Current Neurology and Neuroscience Reports</i> , 2002, 2, 267-276.	4.2	6
230	â€œImportance samplingâ€: A strategy to overcome the clinical/MRI paradox in MS?. <i>Journal of the Neurological Sciences</i> , 2005, 237, 1-3.	0.6	6
231	Atlas-Based Versus Individual-Based Fiber Tracking of the Corpus Callosum in Patients with Multiple Sclerosis: Reliability and Clinical Correlations. <i>Journal of Neuroimaging</i> , 2012, 22, 355-364.	2.0	6
232	6-Month Effects of Fingolimod on Indexes of Cardiovascular Autonomic Control in Multiple Sclerosis. <i>Journal of the American College of Cardiology</i> , 2016, 68, 2027-2029.	2.8	6
233	Assessing balance in non-disabled subjects with multiple sclerosis: Validation of the Fullerton Advanced Balance Scale. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 42, 102085.	2.0	6
234	Modelling new enhancing MRI lesion counts in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2001, 7, 298-304.	3.0	6

#	ARTICLE	IF	CITATIONS
235	Glatiramer acetate in multiple sclerosis. <i>Expert Review of Neurotherapeutics</i> , 2005, 5, 451-458.	2.8	5
236	The definition of non-responder to multiple sclerosis treatment: neuroimaging markers. <i>Neurological Sciences</i> , 2008, 29, 222-224.	1.9	5
237	The Peripheral Network between Oxidative Stress and Inflammation in Multiple Sclerosis. <i>European Journal of Inflammation</i> , 2014, 12, 351-363.	0.5	5
238	Acute Fingolimod Effects on Baroreflex and Cardiovascular Autonomic Control in Multiple Sclerosis. <i>Journal of Central Nervous System Disease</i> , 2019, 11, 117957351984994.	1.9	5
239	Nabiximols discontinuation rate in a large population of patients with multiple sclerosis: a 18-month multicentre study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2020, 91, 914-920.	1.9	5
240	Impaired heart rate recovery after sub-maximal physical exercise in people with multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 40, 101960.	2.0	5
241	Neuroplasticity and Motor Rehabilitation in Multiple Sclerosis: A Systematic Review on MRI Markers of Functional and Structural Changes. <i>Frontiers in Neuroscience</i> , 2021, 15, 707675.	2.8	5
242	Walking With Horizontal Head Turns Is Impaired in Persons With Early-Stage Multiple Sclerosis Showing Normal Locomotion. <i>Frontiers in Neurology</i> , 2021, 12, 821640.	2.4	5
243	Physical activity in non-disabled people with early multiple sclerosis: A multicenter cross-sectional study. <i>Multiple Sclerosis and Related Disorders</i> , 2022, 64, 103941.	2.0	5
244	EEG correlates of cognitive impairment in MS. <i>Italian Journal of Neurological Sciences</i> , 1998, 19, S413-S417.	0.1	4
245	Detecting New Lesion Formation in Multiple Sclerosis: The Relative Contributions of Monthly Dual-Echo and T <sub>1</sub> -Weighted Scans after Triple-Dose Gadolinium. <i>European Neurology</i> , 1998, 40, 146-150.	1.4	4
246	A longitudinal study comparing the sensitivity of CSE and RARE sequences in detecting new multiple sclerosis lesions. <i>Magnetic Resonance Imaging</i> , 1999, 17, 457-458.	1.8	4
247	Neuroimaging techniques in the diagnostic work-up of patients with the antiphospholipid syndrome. <i>Current Rheumatology Reports</i> , 2001, 3, 301-306.	4.7	4
248	A semi-automated measuring system of brain diffusion and perfusion magnetic resonance imaging abnormalities in patients with multiple sclerosis based on the integration of coregistration and tissue segmentation procedures. <i>BMC Medical Imaging</i> , 2016, 16, 4.	2.7	4
249	The still under-investigated role of cognitive deficits in PML diagnosis. <i>Multiple Sclerosis and Demyelinating Disorders</i> , 2017, 2, .	1.1	4
250	Multidisciplinary Rehabilitation is Efficacious and Induces Neural Plasticity in Multiple Sclerosis even when Complicated by Progressive Multifocal Leukoencephalopathy. <i>Frontiers in Neurology</i> , 2017, 8, 491.	2.4	4
251	Predictors of hospital-based multidisciplinary rehabilitation effects in persons with multiple sclerosis: a large-scale, single-centre study. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2019, 5, 205521731984367.	1.0	4
252	MR-based technology for in vivo detection, characterization, and quantification of pathology of relapsing-remitting multiple sclerosis. <i>Journal of Rehabilitation Research and Development</i> , 2002, 39, 243-59.	1.6	4

#	ARTICLE	IF	CITATIONS
253	How does brain MRI lesion volume change on serial scans in patients with multiple sclerosis?. Magnetic Resonance Imaging, 1998, 16, 1181-1183.	1.8	3
254	Brain MRI lesion volume measurement reproducibility is not dependent on the disease burden in patients with multiple sclerosis. Magnetic Resonance Imaging, 1998, 16, 1185-1189.	1.8	3
255	Effects of voice rehabilitation in people with MS: A double-blinded long-term randomized controlled trial. Multiple Sclerosis Journal, 2022, 28, 1081-1090.	3.0	3
256	Brain MRI follow-up of patients with persistent isolated optic neuritis. European Journal of Neurology, 1996, 3, 36-39.	3.3	2
257	Intra-observer, inter-observer and inter-scanner variations in brain MRI volume measurements in multiple sclerosis. Multiple Sclerosis Journal, 2001, 7, 27-31.	3.0	2
258	The influence of slice orientation on brain MRI lesion load measurement in multiple sclerosis. Multiple Sclerosis Journal, 1997, 3, 382-384.	3.0	1
259	Atlas-based vs. individual-based deterministic tractography of corpus callosum in multiple sclerosis. , 2009, 2009, 2699-702.		1
260	Modular organization of lower limbs in persons with multiple sclerosis and healthy persons during walking. Gait and Posture, 2015, 42, S14-S15.	1.4	1
261	Response to Letter "Prediction of Falls in Subjects Suffering From Parkinson Disease, Multiple Sclerosis, and Stroke: Methodologic Issues" Archives of Physical Medicine and Rehabilitation, 2018, 99, 1688-1689.	0.9	1
262	Retrospectively acquired cohort study to evaluate the long-term impact of two different treatment strategies on disability outcomes in patients with relapsing multiple sclerosis (RE.LO.DI.MS): data from the Italian MS Register. Journal of Neurology, 2019, 266, 3098-3107.	3.6	1
263	The IN-DEEP project "Integrating and Deriving Evidence, Experiences, Preferences" a web information model on magnetic resonance imaging for people with multiple sclerosis. Journal of Neurology, 2020, 267, 2421-2431.	3.6	1
264	A theory of mind training for people with multiple sclerosis: Development of a scale to assess the treatment acceptability. Current Psychology, 0, , 1.	2.8	1
265	Diffusion imaging in demyelination and inflammation. , 2004, , 444-459.		0
266	Diffusion and perfusion MRI in inflammation and demyelination. , 0, , 488-500.		0
267	Surface-based reconstruction and diffusion MRI in the assessment of gray and white matter damage in multiple sclerosis. , 2014, , .		0
268	A role for regulatory B cells in preventing the progression of Multiple Sclerosis. Journal of Neuroimmunology, 2014, 275, 12-13.	2.3	0
269	Up-regulation of Nod Like Receptors-3 signaling in multiple sclerosis disease. Journal of Neuroimmunology, 2014, 275, 87.	2.3	0
270	Response to letter regarding article "Fingolimod effects on left ventricular function in multiple sclerosis"™. Multiple Sclerosis Journal, 2016, 22, 708-709.	3.0	0



#	ARTICLE	IF	CITATIONS
271	Diffusion-Weighted Imaging. , 2007, , 65-74.		0
272	White Matter Pathology in Systemic Immune-Mediated Diseases. , 2005, , 343-352.		0